Cisplatin News and Research

RSS

Blocking p300 restores chemotherapy sensitivity in resistant tumors

Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers.

6 Feb 2026

Genetic insights into vestibular system damage from ototoxic drugs

The vestibular system is responsible for the sense of balance in the inner ear. Prolonged use of toxic substances, such as certain antibiotics or anticancer drugs, can damage the hair cells that form part of this system, leading to alterations in balance and other motor skills.

31 Oct 2025

Discovery of EUDAL reveals new mechanism behind chemotherapy resistance in oral cancer

Oral cancer is one of the most common head and neck cancers worldwide, with hundreds of thousands of new cases diagnosed every year. Despite advances in surgery, radiotherapy, and chemotherapy, survival rates remain poor.

30 Sep 2025

Proton therapy and IMRT show similar outcomes in head and neck cancer trial

A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer.

29 Sep 2025

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New therapies for acute kidney injury show promise

Acute kidney injury (AKI) is a severe renal disorder affecting approximately 10%-15% of hospitalized patients and up to 50% in intensive care units (ICUs). Its pathogenesis involves complex inflammatory regulatory mechanisms. As core components of the cytokine network, interleukins (ILs) exert pleiotropic effects in AKI development, extensively participating in inflammation, fibrosis, tissue injury repair, and remote organ damage.

18 Aug 2025

Diagnostic mimicry and management of rare pure form of ovarian cancer

A new case report was published in Volume 12 of Oncoscience on July 28, 2025, titled "A rare case of pure non-gestational ovarian choriocarcinoma: Diagnostic mimicry and management strategies."

14 Aug 2025

Lauric acid could be a key cancer-fighting compound in coconut oil

Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.

11 Aug 2025

Deep learning model predicts adverse drug reactions from chemical structure

Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide. Conventional approaches often fail to detect rare or delayed effects of medicinal products.

7 Aug 2025

Starfish compound overcomes drug resistance in prostate cancer models

Researchers identified that triterpene glycosides from the starfish Solaster pacificus can kill drug-resistant prostate cancer cells in vitro by bypassing common resistance pathways. CuC1 showed synergy with existing chemotherapies, though with only moderate selectivity for cancer cells.

5 Aug 2025

CPADS enables comprehensive analysis of drug resistance across 44 cancer types

CPADS integrates data from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and the Genomics of Drug Sensitivity in Cancer (GDSC) databases, encompassing over 29,000 samples across 44 cancer types and involving 288 drugs. It provides five main analysis modules: differential expression analysis, correlation analysis, pathway analysis, drug analysis, and gene perturbation analysis.

30 Jul 2025

Restoring mitochondria enhances immune response against lung cancer

While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for long-term control.

28 Jul 2025

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

Combination therapy sets new survival standard for advanced biliary tract cancer

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis.

10 Jul 2025

Scientists reveal how chemotherapy causes genetic damage in healthy blood

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

2 Jul 2025

Advancing treatment for urothelial cancer with enfortumab vedotin and pembrolizumab

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy."

2 Jul 2025

Targeting mitochondrial dynamics to combat breast cancer metastasis

Breast cancer, particularly triple-negative breast cancer (TNBC), remains a leading cause of cancer-related mortality due to its aggressive nature and limited therapeutic targets.

27 Jun 2025

Study finds overlap between chemotherapy side effects and brain aging

While chemotherapy can be lifesaving, it also damages DNA and leads to cognitive issues known as "chemo brain." These effects resemble the memory and learning problems seen in older adults, prompting University of Oklahoma researchers to investigate this unique overlap of cognitive decline.

26 Jun 2025